Breast milk drug check: risankizumab levels measured in moms with IBD
NCT ID NCT06346288
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This study looked at how much of the drug risankizumab passes into breast milk of women with inflammatory bowel disease (IBD). Ten mothers who were already taking risankizumab every 8 weeks after giving birth provided milk samples. The goal was to understand infant exposure and check for any side effects in the babies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shaare Zedek Medical Center /ID# 262738
Jerusalem, Jerusalem, 91031, Israel
-
UTHealth Women's Research Program - Memorial City /ID# 263939
Houston, Texas, 77024, United States
-
University of North Carolina at Chapel Hill /ID# 263316
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.